National Stroke Foundation

Zomig (zolmitriptan)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.


Approval Status:

Approved November 1997

Specific Treatments:


Therapeutic Areas

General Information

ZOMIG 2.5 mg and 5.0 mg tablets, an oral medication for the treatment of acute migraine with or without aura in adults, has been approved by the FDA.

Clinical Results

In the ZOMIG clinical program which included eight placebo and non-placebo controlled clinical trials, and a one year open label safety study enrolling more than 4,700 patients, the safety and efficacy of ZOMIG was assessed. In the five placebo-controlled trials, results showed that ZOMIG provided headache relief two hours after treatment significantly more often than placebo.

Side Effects

Adverse events reported by patients were mostly mild or of moderate intensity and the most common included asthenia (lack of energy), nausea, dizziness, somnolence (drowsiness), and paresthesia (feelings such as tingling, numbness, or itching).